News
Bayer Receives FDA Approval for Jivi, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen
Industry News & Research
Jivi’s extended half-life allows for twice-weekly initial dosing and may be adjusted to every five days and further individually adjusted to less…
They Thought Hemophilia Was a ‘Lifelong Thing.’ They May Be Wrong.
Industry News & Research
In a recent New York Times article by Gina Kolata, scientists are edging closer to defeating a longtime enemy of human health:…
UniQure Reports Successful Delivery of FIX Gene Despite Antibodies
Industry News & Research
UniQure presented new hemophilia B clinical trial data on May 19, 2018 at the American Society of Gene and Cell Therapy (ASGCT)…
HTC Investigators Look at Rates of Cardiovascular Disease in Hemophilia Patients
Industry News & Research
Because of their lower factor levels, hemophilia patients are generally thought to be better protected from cardiovascular disease (CVD). To determine whether…
Prophylaxis Study Results for Boys with Severe Hemophilia A
Industry News & Research
A group of Canadian researchers recently published findings from a clinical study on the use of prophylaxis with a standard half-life recombinant…
New Study on Aging, VWF Levels and Bleeding Risk
Industry News & Research
Investigators from the Hemophilia Center of Western Pennsylvania (HCWP) recently looked at the effect of aging on von Willebrand factor (VWF) levels…